# One-Step Chromatographic Approach for Purifying Peptides and Proteins from Venoms

Yasmine Boughanmi, Soioulata Aboudou, Kayané Boyadjian, Acil Charouandi, Sarra Bouzid, Thelma Barnetche, Pascal Mansuelle, Régine Lebrun, Didier Gigmes, Harold de Pomyers, et al.

► To cite this version:

Yasmine Boughanmi, Soioulata Aboudou, Kayané Boyadjian, Acil Charouandi, Sarra Bouzid, et al. One-Step Chromatographic Approach for Purifying Peptides and Proteins from Venoms. Separations, 2024, 11 (6), pp.179. 10.3390/separations11060179. hal-04747353

HAL Id: hal-04747353

https://hal.science/hal-04747353v1

Submitted on 22 Oct 2024

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Article

# One-Step Chromatographic Approach for Purifying Peptides and Proteins from Venoms

Yasmine Boughanmi<sup>1,2</sup>, Soioulata Aboudou<sup>2</sup>, Kayané Boyadjian<sup>1,2</sup>, Acil Charouandi<sup>1</sup>, Sarra Bouzid<sup>1</sup>, Thelma Barnetche<sup>1,2</sup>, Pascal Mansuelle<sup>3 ID</sup>, Régine Lebrun<sup>3 ID</sup>, Didier Gigmes<sup>1</sup>, Harold de Pomyers<sup>2</sup> and Kamel Mabrouk<sup>1,* ID</sup>

<figure><img src="image_3.png" /></figure>

check for
updates

**Citation:** Boughanmi, Y.; Aboudou, S.; Boyadjian, K.; Charouandi, A.; Bouzid, S.; Barnetche, T.; Mansuelle, P.; Lebrun, R.; Gigmes, D.; de Pomyers, H.; et al. One-Step Chromatographic Approach for Purifying Peptides and Proteins from Venoms. *Separations* **2024**, *11*, 179.
https://doi.org/10.3390/separations11060179

Academic Editor: Victoria Samanidou

Received: 29 April 2024

Revised: 20 May 2024

Accepted: 28 May 2024

Published: 6 June 2024

<figure><img src="image_4.png" /></figure>

**Copyright:** © 2024 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

**Abstract:** Animal venoms are intricate and teem with potential for groundbreaking medical advancements. Although traditional methods for purifying venom proteins are effective, they usually require complicated, multi-step processes that lead to lower yields. Our study introduces an efficient, one-step technique for extracting venom-derived proteins through reverse-phase high-performance liquid chromatography (RP-HPLC). We carefully optimized the RP-HPLC process, focusing on the gradient elution conditions and the strategic use of our columns' stationary phase characteristics, to enhance the effectiveness of our separations. This enabled us to efficiently isolate six venom proteins: melittin (2.846 kDa) from *Apis mellifera* with a yield of 4.5% and homogeneity of 99%; α-cobratoxin (7.821 kDa) from *Naja kaouthia* with a yield of 15% and homogeneity of 99%; α-bungarotoxin (7.983 kDa) from *Bungarus multicinctus* with a yield of 7% and purity of 99%; calciseptine (7.035 kDa) from *Dendroaspis polylepis* with a yield of 6% and homogeneity of 95%; notexin (13.593 kDa) from *Notechis scutatus* with a yield of 10% and homogeneity of 95%; and CVFm (150 kDa) from *Naja melanoleuca* with a yield of 0.8% and homogeneity of 94%. These were all accomplished in one step. This breakthrough simplifies the purification of venom peptides and proteins, making the process more feasible and economical. It paves the way for developing new drugs and promising treatments that are both more effective and precisely targeted.

**Keywords:** venoms; proteins; purification; HPLC

## 1. Introduction

Venomous creatures, often feared for their potential lethality, have been extensively studied by scientists around the globe who have extracted valuable medicinal components from their venom. This research has led to significant breakthroughs, resulting in the development of drugs that offer substantial health benefits. As a result, several venom-derived compounds have been approved by the Food and Drug Administration (FDA) for treating various conditions. These include Captopril for managing hypertension, Ziconotide for treating severe chronic pain, and Exenatide for diabetes management [1]. Currently, peptides and proteins from animal venoms are contributing significantly across various fields including medicine, research [2–4], diagnostics [5], cosmetics [6], and agriculture [7]. They constitute 90–95% of the dry weight of many venoms and are especially valuable in drug development due to their small size, stability, potency, and specificity [7,8].

However, isolating these toxins is not a straightforward task. Typically found only in small quantities within venom's complex mixtures, their purification poses significant

<footnote n="1">¹ Aix Marseille Univ, CNRS, Institut de Chimie Radiculaire UMR 7273, F-13390 Marseille, France; yasmine.boughanmi@etu.univ-amu.fr (Y.B.); kayaneboyadjian@hotmail.com (K.B.); charouandiacil@gmail.com (A.C.); sarra.bouzid@etu.univ-amu.fr (S.B.); thelma.barnetche@etu.univ-amu.fr (T.B.); didier.gigmes@univ-amu.fr (D.G.)</footnote>

<footnote n="2">² Latoxan, 26800 Portes-lès-Valence, France; soioulata.aboudou@latoxan.com (S.A.); harold.pomyers@latoxan.com (H.d.P.)</footnote>

<footnote n="3">³ Proteomics Platform, Marseille Proteomics (MaP), IMM, FR 3479, CNRS, F-13009 Marseille, France; pmansuelle@imm.cnrs.fr (P.M.); rlebrun@imm.cnrs.fr (R.L.)</footnote>

<footnote>* Correspondence: kamel.mabrouk@univ-amu.fr</footnote>
challenges. According to the literature, multiple methods are often necessary to effectively purify these proteins. The process generally begins with an affinity chromatography step to separate the desired protein from the crude extract, followed by ion-exchange chromatography to eliminate contaminants and impurities. A final "polishing" step [9] involving size-exclusion chromatography is then employed to remove any remaining impurities, ensuring the final product is of high purity. Traditional purification processes involve numerous steps that not only reduce the yield but also incur significant costs and require considerable time. Consequently, in this study, we aimed to develop a more streamlined and rapid purification approach that enhances protein homogeneity and improves the accuracy of protein quantification. Our method primarily utilizes the well-established RP-HPLC technique, which is selected for its high-resolution capabilities. RP-HPLC is particularly effective at distinguishing between small and large polypeptides and often even between those with nearly identical sequences or differing by only a single amino acid (aa) residue, as shown by the separation of insulin variants from rabbits and humans that differ by only a single aa [10]. This technique offers several advantages including enhanced reproducibility, reduced costs, and accelerated analysis. RP-HPLC also uses less toxic mobile phases and features stable stationary phases and straightforward gradient elution, making it an optimal choice for protein purification.

One of the ongoing challenges in purification is maintaining the integrity of proteins or peptides during the process [11]. To address this, we have adhered to specific conditions such as choosing acetonitrile as the organic solvent, which is volatile and easily removed. Its low viscosity minimizes column back-pressure and therefore does not significantly affect the stability of proteins. Stability and activity can also be maintained by selecting the appropriate elution gradients and columns. Indeed, the denaturation of proteins on hydrophobic surfaces is kinetically slow, so choosing a reduced elution gradient reduces the residence time of the protein in the column [11]. Taking all these factors into consideration, venom peptides with molecular weights ranging from 2 kDa to 150 kDa were isolated: (i) The peptide α-Bungarotoxin (α-Bgtx), from *Bungarus multicinctus*, is a neurotoxin composed of 74 amino acids (aa), cross-linked by five disulfide bridges. This peptide acts as an antagonist to acetylcholine (ACh) at the nicotinic acetylcholine receptor (AChR), primarily binding to the α subunits of AChR with very high affinity and in an irreversible manner, leading to paralysis of striated muscles [12]. (ii) The peptide α-Cobratoxin (α-Cbtx) (71 aa cross-linked by five disulfide bridges) is the most lethal component of the venom of the Thai cobra (*Naja kaouthia*), found in many Southern Asian countries [13]. Its main mode of action is through the inhibition of nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction. (iii) Calciseptine, a 60 aa peptide reticulated with four disulfide bonds, functions as a specific inhibitor of L-type Ca²⁺ channels and constitutes 2.8% of the total *Dendroaspis polylepis* venom components [14]. (iv) Melittin, the predominant component of *Apis mellifera* bee venom, constitutes over 40% of its dry weight [15]. Melittin attaches to lipid bilayer membranes, adopts an amphipathic α-helical secondary structure, and alters the permeability barrier. This enables it to exhibit a broad spectrum of biological activities, including antibacterial, anticancer, and anti-inflammatory effects [16]. (v) Notexin is recognized as the most neurotoxic and myotoxic phospholipase A2 (PLA2) enzyme isolated from the venom of the Australian tiger snake, *Notechis scutatus* [17]. This protein comprises a single peptide chain of 119 aa, cross-linked by seven disulfide bridges [18]. (vi) Cobra Venom Factor (CVFm), from *Naja melanoleuca*, is an acidic glycoprotein with a typical MW ranging between 140 and 150 kDa. It is composed of three subunits designated as alpha, beta, and gamma, with MWs of approximately 70 kDa, 50 kDa, and 30 kDa, respectively [19].

## 2. Materials and Methods

### 2.1. RP-HPLC Purification

Solvents were purchased from Sigma-Aldrich (Saint-Quentin-Fallavier, France) and crude venoms were supplied by Latoxan (Portes lès Valence, France). To purify our molecules, venoms of *Bungarus multicinctus*, *Dendroaspis polylepis*, *polylepis*, *Apis Mellifera*,
Naja kaouthia, Naja melanoleuca, and *Notechis scutatus* (50 mg), solubilized in water at a concentration of 10 mg/mL, were filtered through 0.45-micron filters. The proteins were purified from the filtrates using RP-HPLC on RP columns and the fractions collected every 0.1 min (Table 1). Commercial proteins were used as references during the experiments. The co-elution of our purified molecules with the references allowed for quicker localization.

<table><caption>**Table 1.** Summary of the purification conditions for the 6 venom proteins. The solvents used were B (10% H₂O, 0.1% TFA (v/v) in acetonitrile) in A (0.1% TFA (v/v) in water) at a flow rate of 6 mL/min. * Buffer B for α-Bgtx was 0.1% TFA (v/v) in acetonitrile. The absorbance was monitored by a UV-VIS detector at 214 and 280 nm.</caption><thead><tr><th>Protein-MW (kDa)</th><th>Venom</th><th>Preparative Conditions<br>Agilent 1260 Infinity<br>(Agilent Technologies,<br>Santa Clara, CA, USA)</th><th>Analytical Conditions<br>Shimadzu<br>LC-2010 HPLC<br>(Shimadzu, Kyoto, Japan)</th><th>Retention Time (min)</th><th>Homogeneity/<br>Yield</th></tr></thead><tbody><tr><td>α-bungarotoxin<br>7.983</td><td>Bungarus<br>multicinctus</td><td>- Phenomenex Jupiter 300A 5 µm C18<br>250 mm × 21.2 mm<br>- Gradient (A) 20–45% B * (200 min)</td><td>- Phenomenex Jupiter® 5 µm C18 300<br>Å 250 × 4.6 mm<br>- (G) 0–60% B (60 min)</td><td>35</td><td>99%—7%</td></tr><tr><td>α-Cobratoxin-7.821</td><td>Naja kaouthia</td><td>- Phenomenex Jupiter 300A 5 µm C18<br>250 mm × 21.2 mm<br>- (B) 22–50% B (60 min)</td><td>- Purospher® STAR RP-18<br>250 × 4.6 mm<br>(Merck, Darmstadt, Germany)<br>- (H) 22–50% B (60 min)</td><td>24.5</td><td>99%—15%</td></tr><tr><td>Calciseptine-7.035</td><td>Dendroaspis polylepis<br>polylepis</td><td>- Phenomenex Jupiter 300A 5 µm C18<br>250 mm × 21.2 mm<br>- (C) 20–60% B (160 min)</td><td>- MACHEREY-NAGEL NUCLEOSIL<br>100-5 C18, 5 µm, 250 × 4.6 mm<br>(Düren, Germany)<br>- Gradient G</td><td>36</td><td>95%—6%</td></tr><tr><td>Melittin-2.846</td><td>Apis mellifera</td><td>- Phenomenex Jupiter 300A 5 µm C18<br>250 mm × 21.2 mm<br>- (D) 0–30% (30 min) to 60% B (120 min)</td><td>- MACHEREY-NAGEL NUCLEOSIL<br>100-5 C18, 5 µm, 250 × 4.6 mm<br>(Düren, Germany)<br>- Gradient G</td><td>21.7</td><td>99%—4.5%</td></tr><tr><td>Notexin-13.593<br>(Np and Ns)</td><td>Notechis<br>scutatus</td><td>- Phenomenex Jupiter 300A 5 µm C18<br>250 mm × 21.2 mm<br>- (E) 20–40% B (40 min)</td><td>- AdvanceBio RPmAb Diphenyl<br>150 × 4.6 mm (Agilent Technologies,<br>Santa Clara, CA, USA)<br>- (I) 20–40% B (20 min)</td><td>12.6</td><td>95%—10%</td></tr><tr><td>CVFm-150</td><td>Naja<br>melanoleuca</td><td>- Agilent ZORBAX 300SB-C3<br>250 × 21.2 mm 7µ (Agilent<br>Technologies, Santa Clara, CA, USA)<br>- (F) 0–100% B (100 min)</td><td>- AdvanceBio RPmAb Diphenyl<br>150 × 4.6 mm<br>- (J) 30–60% B (30 min)</td><td>23</td><td>94%—0.8%</td></tr></tbody></table>

SDS-PAGE of CVFm was conducted using a 10% acrylamide gel under non-reducing and reducing (50 mM dithiothreitol) conditions following the method outlined by Laemmli [20].

## 2.2. Mass Spectrometry Analysis

The isolated peptides, with the exception of CVFm, were characterized by spectrometry MALDI-ToF using an α-cyanohydrocinnamic acid (HCCA) matrix (0.7–1 µL equal volumes of saturated solution at 10 µg/µL in MeCN or in 50% MeCN/0.3% TFA/H₂O). Spectra recorded in linear positive method LP12 kDa (Bruker microflex) or HMASS 5–20 kDa were externally calibrated with suitable standards as Prot col I of Brucker with a laser (λ = 337 nm, W = 75.2 µJ, 500 shots of v = 10 Hz), and were analyzed by a Bruker Daltonics flex analysis software Flex Control 1.2 SP1 version 3.0 (2008) (Bruker, Palaiseau, France).

MALDI-ToF MS analysis was performed as previously described by Krayem et al. [21]. Proteomic analyses after trypsin digestion and tandem mass spectrometry (MS/MS) were performed as previously described by Kpebe et al. except for the searched taxonomy [22].

## 3. Results and Discussion

It is crucial to note that we initially used C18 100 Å columns for all short peptides except for notexin and CVFm. The outcomes were not very satisfactory for us. Consequently, we used a preparative column with larger pore silicas, specifically a C18 with 300 Å. Indeed, it is believed that materials with wider pores more effectively facilitate the entry of larger proteins into the porous matrix and enhance the partitioning between phases [10].
### 3.1. Purification of α-Bungarotoxin (α-Bgtx)

The purification of α-Bgtx was carried out in multiple stages. Eterović et al. (1975) and Hanley et al. (1977) used ion-exchange chromatography on a CM-Sephadex column combined with CM-cellulose chromatography [23] to achieve a yield of 27% [24] and a purity of 90% [25]. Similarly, Mebs et al. employed two CM-Sephadex C-25 or C-50 cation-exchange columns and two Sephadex G-25 columns for desalting the samples. With this method, the purified, desalted, and lyophilized toxin was obtained with a yield corresponding to about 15 to 20% of the weight of the lyophilized venom [26]. In our case, the focus was on purifying α-Bgtx using only a single chromatographic step to achieve higher homogeneity rates than those previously published. A comparative study of three different chromatographic columns (Figure 1), a Jupiter C18 300 Å 5 µm column (a), a Nucleosil C18 300 Å 5 µm column (b), and a ZORBAX C3 SB 300 Å 5 µm column (c), was conducted using analytical HPLC with an identical acetonitrile gradient A.

<figure><img src="image_5.png" /><figcaption>**Figure 1.** Elution of *Bungarus multicinctus* venom on columns a, b, and c using 0% to 15%B for 30 min to 45% for 240 min gradient at 214 nm. Arrows indicate α-Bgtx.</figcaption></figure>

The comparison of the spectra revealed that the α-Bgtx peak obtained with the C3 ZORBAX SB 300 Å 5 µm column (Figure 1c), eluted at an intermediate time (120 min), was contaminated before and after. α-Bgtx is highly retained on the Nucleosil C18 Htec column (123 min) and exhibits contaminant peaks beforehand. The Jupiter C18 300 Å 5 µm column generates the following: (i) better separation and resolution of the peak corresponding to α-Bgtx, leading to (ii) higher purity and (iii) better yield. In addition, α-Bgtx eluted faster than on the two other columns (80 min). Although the Jupiter C18 300 Å and Nucleosil C18 300 Å columns have very similar characteristics and are end-capped, the chromatographic profile of α-Bgtx differs between them. These elution differences can be explained by several hypotheses: (i) the density of C18 grafting and the end-capping between the columns can influence how the molecule interacts with the stationary phase; (ii) variations in pore size, particle size, and particle shape between the columns can affect resolution and separation efficiency; and finally, (iii) the presence of uncapped silanols or other specific interactions at each column might also vary and influence the results. The Jupiter C18 300 column thus allowed us to purify the batch of venom from *Bungarus multicinctus* (Figure 2) with a yield of 7% and a homogeneity exceeding 99% (Figure 3). This purity was confirmed by MALDI-ToF mass spectrometry ([M + 1H] = 7.984 Da) (Figure 4).
<figure><img src="image_6.png" /><figcaption>**Figure 2.** α-Bgtx purification: preparative HPLC chromatogram of *Bungarus multicinctus* venom using gradient A at 214 nm.</figcaption></figure>

<figure><img src="image_7.png" /><figcaption>**Figure 3.** Analytical HPLC profile of α-Bgtx on column c with a gradient G at 214 nm.</figcaption></figure>

<figure><img src="image_8.png" /><figcaption>**Figure 4.** Mass spectrum of α-Bgtx using MALDI-ToF.</figcaption></figure>

### 3.2. Purification of α-Cobratoxin (α-Cbtx)

Isolation procedures for this protein, as reported in the literature, are generally similar, varying only in the columns and solvents used. For example, Kukhtina et al. [27] utilized two methods to isolate α-Cbtx from *Naja kaouthia's* venom. Initially, the venom was separated by gel filtration on a Sephadex G-50sf column. Fraction III, which contained all the
proteins, was further purified by high-performance ion-exchange chromatography using a HEMA 1000BIO CM column. The molecular masses of the fractions were determined by MALDI-ToF MS analysis, and Fraction 3 was confirmed to be α-Cbtx. These fractions were ultimately purified using RP-HPLC on a Vydac C18 column. In the second method, crude venom was loaded onto a BioRex 70 cation exchanger equilibrated with ammonium acetate buffer. Separation was achieved using a gradient of increasing buffer molarity. The obtained fractions were analyzed by MS, and Fraction 4 was identified as α-Cbtx. The purity levels of these purification methods were not determined in the article [27].

Our group employed an efficient, one-step method. *Naja kaouthia's* venom was purified exclusively on an RP-HPLC system. The MWs of the fractions from each peak were determined by MALDI-ToF (data not shown), and the peak, eluted at 37% of solvent B, shown in Figure 5, was assigned to α-Cbtx. Fractions from this peak were pooled, and a homogeneity of more than 99% was verified by analytical RP-HPLC (Figure 6).

<figure><img src="image_9.png" /><figcaption>**Figure 5.** α-Cbtx purification: preparative HPLC chromatogram of *Naja kaouthia* venom using gradient B at 214 nm.</figcaption></figure>

<figure><img src="image_10.png" /><figcaption>**Figure 6.** Analytical HPLC profile of α-Cbtx using gradient H at 214 nm.</figcaption></figure>

This singular purification step, characterized by its simplicity, speed, and reproducibility, enabled the isolation of α-Cbtx with a yield of 15%.
### 3.3. Purification of Calciseptine

The original purification process for calciseptine from the raw venom involved four crucial steps: (i) gel filtration on Sephadex 50, (ii) ion-exchange chromatography using TSK SP 5PW, (iii) HPLC on an RP-18 column, and (iv) desalination on a Trisacryl GF05 M column [28].

In our case, *Dendroaspis polylepis polylepis's* venom was purified exclusively on the RP-HPLC system.

Using commercially available calciseptine as a reference, we identified and isolated the specific fraction containing calciseptine through preparative HPLC, with segmentation performed at 0.1 min intervals (Figure 7). This targeted fraction was eluted at 30% using a slope of 0.25% (gradient C). Calciseptine was obtained with a purity exceeding 95% and a yield of 6% (Figure 8).

<figure><img src="image_11.png" /><figcaption>**Figure 7.** Calciseptine purification: preparative HPLC profile of *Dendroaspis polylepis polylepis* using gradient C at 214 nm.</figcaption></figure>

<figure><img src="image_12.png" /><figcaption>**Figure 8.** Analytical HPLC profile of calciseptine obtained with gradient G at 214 nm.</figcaption></figure>
The experimental mass obtained by MALDI-ToF ([M + 1H] = 7.036 Da) corresponds closely with the theoretical mass of calciseptine (7035 Da) (Figure 9).

<figure><img src="image_13.png" /><figcaption>**Figure 9.** Mass spectrum of calciseptine using MALDI-ToF.</figcaption></figure>

### 3.4. Purification of Melittin

Han et al. employed a multi-step purification process for melittin. Initially, the venom was fractionated using a Superdex peptide HE 10/30 column, followed by further purification on a PepRPC HR 10/10 column, and finally, the purified product was obtained through a Superdex 75 10/300 GL column. However, the description provided did not include data regarding yield and purity [15].

In contrast, Teoh et al. described a single-step purification method for melittin utilizing a HiTrap SP FF cation-exchange column. This approach achieved a purity of 93% for the peptide [29]. Nevertheless, this study omitted a desalting step, particularly considering the use of NaCl, which was not addressed in their report.

Melittin was purified with a yield of 4.5% on a Jupiter C18 300A column using gradient D with a slope of 0.25% B (Figure 10). Its homogeneity exceeding 99% was controlled using analytical RP-HPLC on a C18 column (Figure 11) and the purity was confirmed through MALDI-ToF [M + 1H] = 2845 Da (Figure 12).
<figure><img src="image_14.png" /><figcaption>**Figure 10.** Melittin purification: preparative HPLC profile of *Apis mellifera* venom using gradient D at 214 nm.</figcaption></figure>

<figure><img src="image_15.png" /><figcaption>**Figure 11.** Analytical HPLC profile of melittin using gradient G at 214 nm.</figcaption></figure>

<figure><img src="image_16.png" /><figcaption>**Figure 12.** MALDI-ToF mass spectrum of melittin.</figcaption></figure>
### 3.5. Purification of Notexin

Traditionally, isolation of notexin involved techniques such as gel filtration, high-performance ion exchange, and RP-HPLC. The protein was initially purified using cation-exchange chromatography on Bio-Rex 70 with an ammonium acetate gradient. The primary toxic component of the tiger snake venom was chromatographed on Sephadex G-50, and the principal peak, which was confirmed as notexin, showed a purity greater than 97% [18]. Chwetzoff et al. [30] noted that the ion-exchange fraction containing notexin comprised multiple components, leading to a reassessment of the initial purification method. Consequently, the fraction with notexin was further separated by RP-HPLC on a Nucleosil butyl large-pore column to distinguish between Notechis Np and Notechis Ns [30]. Indeed, Chwetzoff et al. demonstrated that Notechis Np and notexin share the same sequence, thus representing the same molecule. However, through Edman sequencing, they discovered that Notechis Ns differs by a single aa at position 16, where a lysine is replaced by an arginine. Nevertheless, this difference between the two isomers, Ns and Np, does not result in any variance in their presynaptic and myotoxic activities. The amount of Notechis Ns ranged from 38% to 6% of the total notexin content [30]. Although notexin can be isolated directly by ion-exchange chromatography of the crude venom, Halpert et al. first employed gel filtration on Sephadex G-75 to simplify its isolation, achieving a yield of 6.7% [31].

In a separate study, Yang and Chang [32] purified the toxin from tiger snake venom using SP-Sephadex C-25 instead of following the method of gel filtration on Sephadex G-25 and subsequent ion-exchange chromatography on Bio-Rex 70, as previously described by Halpert et al. [31]. Unlike the common use of these complex multi-step protocols, our approach enabled notexin Ns and Np to be purified in a single step using an RP-HPLC system (Figures 13 and 14).

<figure><img src="image_17.png" /><figcaption>**Figure 13.** (A) Notexin purification: preparative HPLC profile of *Notechis scutatus* venom using gradient E at 214 nm. (B) Enlargement of the notexin elution region.</figcaption></figure>

The homogeneity of notexin was evaluated using analytical RP-HPLC as illustrated in Figure 14 below: notexin Np was eluted at 12.6 min and represents 76%. As for notexin Ns, it was eluted at 12.9 min and represents 20%.
<figure><img src="image_18.png" /><figcaption>**Figure 14.** Analytical HPLC profile of notexin using a gradient I at 214 nm.</figcaption></figure>

Notexin (Np and Ns) was obtained with a yield of 10% with a homogeneity exceeding 95%, compared to the 6.7% yield achieved by Halpert et al. [31].

### 3.6. Purification of CVFm

V. Osipov et al. [19] extracted Cobra Venom Factor (CVF) from *Naja melanoleuca* venom using a multi-step purification process. The process began with the venom being dissolved and filtered through a Sephadex G50 superfine column. The fractions collected were then concentrated and further purified using a HEMA 1000BIO DEAE column. Following additional concentration and desalination, the samples underwent rechromatography on the same type of column but with a modified gradient. The final step involved desalting and drying the purified CVF for further analysis [19].

In our study, we successfully isolated this molecule in a single step using RP-HPLC on a Zorbax SB C3 300 Å column (Figure 15). Our choice was based on this column for two main reasons: (i) The larger pores of the Zorbax SB C3 300 Å allow better penetration and interaction of the protein with the stationary phase, which is crucial for proteins of size like 150 kDa. (ii) The C3 column utilizes propyl chains (C3), which offer lower hydrophobicity compared to C18 columns. This can be beneficial for proteins, as excessive hydrophobicity may lead to overly strong interactions and potentially cause issues with protein denaturation or incomplete recovery. The moderate hydrophobicity facilitates a gentler and more specific elution.

Subsequently, the purified protein is characterized using SDS-PAGE under both non-reduced and reduced conditions. The gel revealed a single band at approximately 150 kDa under non-reducing conditions and three major bands around 70, 50, and 30 kDa under reducing conditions, as illustrated in Figure 16. These findings align with those reported by V. Osipov et al. who observed bands at similar molecular weights (65–70, 50, and 30 kDa) [19]. Tryptic digestion of the isolated bands and their identification was performed as shown in Figure 16.
<figure><img src="image_19.png" /><figcaption>**Figure 15.** CVFm purification: preparative chromatogram of *Naja melanoleuca* venom using gradient F at 214 nm. The position of CVFm is indicated by an arrow.</figcaption></figure>

<figure><img src="image_20.png" /><figcaption>**Figure 16.** SDS-PAGE of CVFm with three lanes labeled A, B, and C. Lane C is the molecular weight marker, as indicated by the distinct bands labeled with corresponding molecular weights (250 kDa down to 25 kDa). Lane B represents the sample under non-reducing conditions and Lane A under reducing conditions.</figcaption></figure>

It should be noted that the sequence of CVFm has not been previously described, though it shows a similarity to that of CVFk, with a homology of 35% as identified by trypsin/LysC digestion and analyzed by ESI-Q-Exactive MS/MS (Figure 17).
<table><thead><tr><th>Band (kDa)</th><th>Identity</th><th>Sequence</th></tr></thead><tbody><tr><td>NR-200</td><td>CVFm</td><td>MERMALYLVA ALLIGFPGSS HGALYTLTP AVLRTDTEEQ ILVEAHGDEST PKQLDIFVHD FPRKQKTLFQ TRVDMNPAGG MLVPTIEIP AKEVSTDSRQ NQYVVVQVTG PQVRLEKVVL LSYQSSFLFI QTDKGIYTPG SPVLYRVFSM DHNTSKMNKT VIVEFQTPEG ILVSSNSVDL NFFWYPYNLPD LVSGTGRIV AKYEHSPENY TAYFDVRKYV LPSFEVRLOP SEKFEYIDGN ENFHVSITAR YLYGEEVEGV AFVLFGVKID DAKKISPIDSL TRIPIIDGDG KATLKRDTRF SRFPNLNELV GHTLYASVTV MTESGSDMVV TEQSGIHIVA SPYQIHFTKT PKYFKPGMPY ELTVYVTNPD GPAAHVPVV SEAFHSMGTT LSDGTAKLIL NIPLNAQSLP ITVRTNHGDL PRERQATKSM TAIAYQTQGG SGNYLHVAIT STEIKPGDNL PVNFNVKGNA NSLKQIKYFT YLILNKGKIF KVGRQPRRDG QNLVTVMNLI TPDLIPSFRFVAYYQVGNNE IVADSVWVDV KDTCMGLTVV KGDNLIQMPG AAMKIKLEGD PGARVGLVAV DKAVYVLNDK YKISQAKIWID TIEKSDFGCT AGSGQNNLGV FEDAGLALTT STNLNTKQRS AAKCPQPANR RRRSSVLLLD SNASKAAEFQ DQDLRKCCED VMHENPMGYT CEKRAKYIQE GDACKAAFLE CCRYIKGVRD ENQRESELFL ARDDNEDGFI ADSDIISRSD FPKSWLWLTK DLTEEPNSQG ISSKTMSFYL RDSITTWVVL AVSFPTTKGI CVAEPYEIRV MKVVFFIDLQM PYSVVKNEQV EIRAILHNYN NEDIYVRVEL LYNPAFCSAS TKGQRYRQQF PIKALSSRAV PVFIVPLEQG LHDVEIKASV QEALWSDGVR KKLKVVPEGV QKSIVTIVKL DPRAKGVGGT QLEVIKARKL DDRVPDTEIE TKIIIQGOPV AQIIENSIDG SKLNHLIITP SGCGEQNMR MAAPVIATYY LDTTEQWETL GINRRTEAVN QIVTGYAQQM VYKKADHSYA AFTNRASSSW LTAYVVKVFA MAAKMVAGIS HEIICGGVRW LILNRQQPDG AFKENAPVLS GTMQGGIQGA EEEVYLTAFI LVALLESKTI CNDYVNSLDS SIKKATNYLL KKYEKLQRPY TTALTAYALA AADQLNDDDRV LMAASTGRDH WEEYNAHTHN IEGTSYALLA LLKMKKFDQTGPIVRWLTDQ NFYGETYGQT QATVMAFQAL AYEIEIQMPTH KDLNLDITIE LPDREVPIRY RINYENALLA RTVETKLNQD ITVTASGDGK ATMTILTFTYN AQLQEKANVC NKFHLNVSVE NIHLNAMGAK GALMLKICTR YLGEVDSTMT IIDISMLTGF LPDAEDLTRL SKGVDRYISR YEVDDNMAQK VAVIIYNKLV SHSEDECLHF KILKHFEVGF IQPGSVKVYS YYNLDEKCTK FYHPDKGTGL LNKICIGNVC RCAGETCSSL NHQRERIDVPL QIEKACETNV DYVVYKTKLLR IEEQDGNIDY VMDVLEVIKQ GTDENPRAKT HQYISQRKCQ EALNLKVNDD YLIWGSRSDL LPTKDKISYI ITKNTWIERW PHEDECQEEE FQKLCDFAQ FSYTLTEFGC PT</td></tr><tr><td>R-70</td><td>α Chain</td><td>ALYLTLITPAV LRTDTEEQIL VEAHGDSTPK QLDIFVHDFP RKQKTLFQTR VDMNPAGGML VPTIEIPAK EVSTDSRQNQ YVVVQVTGPQ VRLEKVVLLS YQSSFLFIQT DKGIYTPGSP VLYRVFSMDH NTSKMKNKT VEFQTPEGIL VSSNSVDLNF FWPYNLPDLV SLGTWRIVAK YEHSPENYTA YFDVRKYVLVP SFEVRLQPSE KFFYIDGNEN FHVSITARYL YGEEVEGVAF VLFEGVKIDDA KKSIPDSLTR IPIIDGDGKA TLKRDTFRSR FPNLNELVGH TLYASVTVMT ESGSDMVVTE QSGIHIVASP YQIHFTKTPK YFKPGMPYEL TVYVNTPDGS PAAHVVPVSE AFHSMGTTLS DGTAKLILNI PLNAQSLPIT VRTNHGDLPR ERQATKSMTA IAYQTQGGSG NYLHVAITST EIKPGDNLPV NFNVKGNANS LKQIKYFTYL ILNKGKIFKV GRQPRRDGQN LVMTLNLHITP DLIPSFRFVA YYQVGNNEIV ADSVWVDVKD TCMGTLVVKG DNLIQMPGAA MKIKLEGDPG ARVGLVAVDK AVYVLNDKYK ISQAKIWDTI EKSDFGCTAG SGQNNLGVFE DAGLALTTST NLNTKQRSAA KCPQPAN</td></tr><tr><td>R-50</td><td>β Chain</td><td>EIQMPTHKDL NLDITIELPD REVPIRYRIN YENALLARTV ETKLNQDITV TASGDGKATM TILTFYNAQL QEKANVCNKF HLNVSVENIH LNAMGAKAL MLKICTRYLG EVDSTMTIID ISMLTGFLPD AEDLTRSKG VDRYISRYEVD NNMAQKVAV IIYLKVSHES EDECLHFKIL KHFEVGFIQP GSVKVYSYYN LDEKCTKFYH PDKGTGLLNK ICIGNVCRCA GETCSSLNHQ ERIDVPLQIE KACETNVDYV YTKTLRIEE QDGNDIYVMD VLEVIKQGTD ENPRAKTHQY ISQRKCQEAL NLKVNDDYLI WGSRSDLLPT KDKISYIITK NTWIERWPHE DECQEEEQFQ LCDDFAQFSY TLTEFGCPT</td></tr><tr><td>R-30</td><td>γ Chain</td><td>DDNEDGFIAD SDIISRSDFP KSWLWLTKDL TEEPNSQGIS SKTMSFYLRD SITTWVVLAV SFTPTKGICV AEPYEIRVMK VFFIDLQMPY SVVKNEQVEI RAILHNYVNE DIYVRVELLY NPAFCSASTK GQRYRQQFPFI KALSSRAVPF VIVPLEQGLH DVEIKASVQE ALWSDGVRKK KLKVPEGVQK SIVTIVKLDP RAKGVGGTQL EVIKARKLDD RVPDTEIETK IIIQGDPAVA IIENSIDGSK LNHLIITPSG CGEQNIR</td></tr></tbody></table>

<table><caption>**Figure 17.** Enzymatic digestion results: trypsin/LysC and ESI-Q-Exactive (MS/MSMS).</caption><thead><tr><th>Band</th><th>Description</th></tr></thead><tbody><tr><td>NR-150</td><td>Cobra venom factor precursor, Chain F - Cobra venom factor, complement C3 precursor</td></tr><tr><td>R-70</td><td>Cobra venom factor precursor, Chain F - Cobra venom factor, complement C3 precursor</td></tr><tr><td>R-50</td><td>Cobra venom factor precursor, Chain H - Cobra venom factor, Chain F - Cobra venom factor, complement C3 precursor</td></tr><tr><td>R-30</td><td>Cobra venom factor precursor</td></tr></tbody></table>

Indeed, in column B, the band observed between 150 and 200 kDa represents CVFm. Meanwhile, in column A, the bands at approximately 70, 50, and 30 kDa correspond to the α, β, and γ subunits of CVFm, respectively. In summary, the CVFm isolated through a single RP-HPLC step and subsequently analyzed via analytical HPLC showed a purity exceeding 94% (Figure 18). The yield achieved was 0.8%, which slightly surpasses the results reported by V. Osipov et al. However, it should be noted that they did not provide purity levels in their study, making a direct comparison of yields between our research and theirs somewhat challenging. No loss of biological activity has been reported for CVFm, nor for the rest of the proteins (data not shown), contrary to what is sometimes described in the literature for large proteins.
<figure><img src="image_21.png" /><figcaption>**Figure 18.** Analytical HPLC profile of CVFm obtained with gradient J at 214 nm.</figcaption></figure>

**4. Conclusions**

Traditional methods for protein purification often involve intricate protocols and extensive preparation, which can significantly prolong the process and escalate costs. In contrast, our study underscores the effectiveness of employing a simplified single-step RP-HPLC method. We utilized straightforward and widely accessible solvent systems, markedly different from the more complex protocols documented in the literature that require intricate salt or pH gradients and labor-intensive setups such as FPLC. Our results suggest that the simplified single-step RP-HPLC method can be used for the rapid separation of proteins from complex mixtures prior to the integration of multiple separation methods. This approach offers a cost-effective and time-efficient alternative, highlighting the significance of our findings in protein purification protocols.

**Author Contributions:** Y.B.: investigation, methodology, writing, review, editing, and purifications of α-Bgtx, calciseptine, α-cobratoxin; S.A.: investigation, writing parent draft, purifications of CVFm, notexin, α-cobratoxin, SDS-PAGE; K.B.: purifications of melittin, α-cobratoxin, CVFm, notexin; A.C.: α-Bgtx, α-cobratoxin; S.B.: purification of calciseptine; T.B.: purification of α-Bgtx; P.M.: mass spectrometry and MS/MS; R.L.: mass spectrometry and review; D.G.: conceptualization and review; H.d.P.: conceptualization and review; K.M.: conceptualization and design of the experiments, writing, review, editing, and final approval. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Data Availability Statement:** The results of this study are fully documented and presented within the confines of this article.

**Conflicts of Interest:** We disclose that the students affiliated to latoxan, who are co-authors of this article, have received scholarships or grants (for thesis work or internships) from Latoxan as part of a collaboration on research projects. However, we affirm that Latoxan did not influence the study design, data collection, analysis, interpretation of data, manuscript writing, or the decision to submit the manuscript for publication.

**References**

1. Morsy, M.A.; Gupta, S.; Dora, C.P.; Jhawat, V.; Dhanawat, M.; Mehta, D.; Gupta, K.; Nair, A.B.; El-Daly, M. Venoms classification and therapeutic uses: A narrative review. *Eur. Rev. Med. Pharmacol. Sci.* **2023**, *27*, 1633–1653. [CrossRef]

2. Mabrouk, K.; Ram, N.; Boisseau, S.; Strappazzon, F.; Rehaim, A.; Sadoul, R.; Darbon, H.; Ronjat, M.; De Waard, M. Critical amino acid residues of maurocalcine involved in pharmacology, lipid interaction and cell penetration. *Biochim. Biophys. Acta Biomembr.* **2007**, *1768*, 2528–2540. [CrossRef] [PubMed]
3. González García, M.C.; Radix, C.; Villard, C.; Breuzard, G.; Mansuelle, P.; Barbier, P.; Tsvetkov, P.O.; De Pomyers, H.; Gigmes, D.; Devred, F.; et al. Myotoxin-3 from the Pacific Rattlesnake *Crotalus oreganus* oreganus Venom Is a New Microtubule-Targeting Agent. *Molecules* **2022**, *27*, 8241. [CrossRef] [PubMed]

4. Chalier, F.; Mugnier, L.; Tarbe, M.; Aboudou, S.; Villard, C.; Kovacic, H.; Gigmes, D.; Mansuelle, P.; de Pomyers, H.; Luis, J.; et al. Isolation of an anti-tumour disintegrin: Dabmaurin-1, a peptide Lebein-1-Like, from *Daboia mauritanica* Venom. *Toxins* **2020**, *12*, 102. [CrossRef] [PubMed]

5. Gosselin, R.C.; Douxfils, J. Ecarin based coagulation testing. *Am. J. Hematol.* **2020**, *95*, 863-869. [CrossRef] [PubMed]

6. Verdoni, M.; Roudaut, H.; De Pomyers, H.; Gigmes, D.; Bertin, D.; Luis, J.; Mabrouk, K. ArgTX-636, a polyamine isolated from spider venom: A novel class of melanogenesis inhibitors. *Bioorg. Med. Chem.* **2016**, *24*, 5685-5692. [CrossRef] [PubMed]

7. Smallwood, T.B.; Clark, R.J. Advances in venom peptide drug discovery: Where are we at and where are we heading? *Expert Opin. Drug Discov.* **2021**, *16*, 1163-1173. [CrossRef]

8. King, G.F. Venoms as a platform for human drugs: Translating toxins into therapeutics. *Expert Opin. Biol. Ther.* **2011**, *11*, 1469-1484. [CrossRef]

9. Thermo Fisher Scientific Inc. Successful Separations of Peptides, Proteins and Other Biomolecules HPLC Analysis of Biomolecules Technical Guide. Available online: www.thermoscientific.com/chromatography (accessed on 25 May 2010).

10. Jean, R.; McClintock, R. Reversed-phase high-performance liquid chromatography of insulins from different species. *J. Chromatogr. A* **1983**, *268*, 112-119.

11. Carr, D. *The Handbook of Analysis and Purification of Peptides and Proteins by Reversed Phase HPLC*; Grace Vydac: Hesperia, CA, USA, 2002; pp. 1-14.

12. Brun, O.; Zoukimian, C.; Oliveira-Mendes, B.; Montnach, J.; Lauzier, B.; Ronjat, M.; Béroud, R.; Lesage, F.; Boturyn, D.; De Waard, M. Chemical Synthesis of a Functional Fluorescent-Tagged α-Bungarotoxin. *Toxins* **2022**, *14*, 79. [CrossRef]

13. Wongtongkam, N.; Wilde, H.; Sitthi-Amorn, C.; Ratanabanangkoon, K. A Study of Thai Cobra (Naja kaouthia) Bites in Thailand. 2005. Available online: https://academic.oup.com/milmed/article/170/4/336/4577729 (accessed on 1 April 2005).

14. de Weille, J.R.; Schweitz, H.; Maes, P.; Tartar, A.; Lazdunski, M. Calciseptine, a peptide isolated from black mamba venom, is a specific blocker of the L-type calcium channel. *Proc. Natl. Acad. Sci. USA* **1991**, *88*, 2437-2440. [CrossRef] [PubMed]

15. Han, S.; Yeo, J.; Baek, H.; Lin, S.M.; Meyer, S.; Molan, P. Postantibiotic effect of purified melittin from honeybee (*Apis mellifera*) venom against *Escherichia coli* and *Staphylococcus aureus*. *J. Asian Nat. Prod. Res.* **2009**, *11*, 796-804. [CrossRef] [PubMed]

16. Guha, S.; Ferrie, R.P.; Ghimire, J.; Ventura, C.R.; Wu, E.; Sun, L.; Kim, S.Y.; Wiedman, G.R.; Hristova, K.; Wimley, W.C. Applications and evolution of melittin, the quintessential membrane active peptide. *Biochem. Pharmacol.* **2021**, *193*, 114769. [CrossRef] [PubMed]

17. Dixon, R.W.; Harris, J.B. Myotoxic activity of the toxic phospholipase, notexin, from the venom of the Australian tiger snake. *J. Neuropathol. Exp. Neurol.* **1996**, *55*, 1230-1237. [CrossRef] [PubMed]

18. Karisson, E.; Eaker, D.; Rydén, L. Purification of a presynaptic neurotoxin from the venom of the Australian tiger snake *Notechis scutatus scutatus*. *Toxicon* **1972**, *10*, 405-413. [CrossRef] [PubMed]

19. Osipov, A.V.; Mordvintsev, D.Y.; Starkov, V.G.; Galebskaya, L.V.; Ryumina, E.V.; Bel'tyukov, P.P.; Kozlov, L.V.; Romanov, S.V.; Doljansky, Y.; Tsetlin, V.I.; et al. *Naja melanoleuca* cobra venom contains two forms of complement-depleting factor (CVF). *Toxicon* **2005**, *46*, 394-403. [CrossRef] [PubMed]

20. Laemmli, U.K. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4. *Nature* **1970**, *227*, 680-685. [CrossRef] [PubMed]

21. Krayem, N.; Parsiegla, G.; Gaussier, H.; Louati, H.; Jallouli, R.; Mansuelle, P.; Carrière, F.; Gargouri, Y. Functional characterization and FTIR-based 3D modeling of full length and truncated forms of Scorpio maurus venom phospholipase A2. *Biochim. Biophys. Acta Gen. Subj.* **2018**, *1862*, 1247-1261. [CrossRef] [PubMed]

22. Kpebe, A.; Guendon, C.; Payne, N.; Ros, J.; Khelil Berbar, M.; Lebrun, R.; Baffert, C.; Shintu, L.; Brugna, M. An essential role of the reversible electron-bifurcating hydrogenase Hnd for ethanol oxidation in *Solidesulfovibrio fructosivorans*. *Front. Microbiol.* **2023**, *14*, 1139276. [CrossRef]

23. Hanley, M.R.; Eterovic, V.A.; Hawkes, S.P.; Hebert, A.J.; Bennett, E.L. Neurotoxins of Bungarus multicinctus venom purification and partial characterization. *Biochemistry* **1977**, *16*, 5840-5849. [CrossRef]

24. Eterovic, V.A.; Hebert, M.S.; Hanley, M.R.; Bennett, E.L. The lethality and spectroscopic properties of toxins from *Bungarus multicinctus* (Blyth) venom*. *Toxicon* **1975**, *13*, 37-48. [CrossRef] [PubMed]

25. Eterović, V.A.; Aune, R.G.; Bennett, E.L. Radioactive Labeling of cx-Bungarotoxin with Tritium. *Anal. Biochem.* **1975**, *68*, 394-403. [CrossRef] [PubMed]

26. Mebs, D.; Nan, K.; Iwanaga, S.; Samejima, Y.; Nan Lee, C. Purification, Properties and Amino Acid Sequence of a-Bungarotoxin from the Venom of *Bungarus multicinctus*. *Biol. Chem.* **1972**, *353*, 243-262.

27. Kukhtina, V.V.; Weise, C.; Muranova, T.A.; Starkov, V.G.; Franke, P.; Hucho, F.; Wnendt, S.; Gillen, C.; Tsetlin, V.I.; Utkin, Y.N. Muscarinic toxin-like proteins from cobra venom. *Eur. J. Biochem.* **2000**, *267*, 6784-6789. [CrossRef] [PubMed]

28. Schweitz, H.; Bidard, J.-N.; Lazdunski, M. Purification and pharmacological characterization of peptide toxins from the black mamba (*Dendroaspis polylepis*) venom. *Toxicon* **1990**, *28*, 847-856. [CrossRef] [PubMed]

29. Teoh, A.C.L.; Ryu, K.H.; Lee, E.G. One-step purification of melittin derived from *Apis mellifera* bee venom. *J. Microbiol. Biotechnol.* **2017**, *27*, 84-91. [CrossRef]
30. Chwetzoff, S.; Mollier, P.; Bouet, F.; Rowan, E.C.; Harvey, A.L. On the purification of notexin Isolation of a single amino acid variant from the venom of *Nutechis scutatus scutatus*. *FEBS Lett.* **1990**, *261*, 226-230. [CrossRef] [PubMed]

31. Halpert, J.; Eaker, D.; Karlsson, E. The role of phospholipase activity in the action of a presynaptic neurotoxin from the venom of *Notechis scutatus scutatus* (Australian tiger Snake). *FEBS Lett.* **1976**, *61*, 72-76. [CrossRef]

32. Yang, C.-C.; Chang, L.-S. The N-terminal amino group essential for the biological activity of notexin from *Notechis scutatus scutatus* venom. *Biochim. Biophys. Acta* **1990**, *1040*, 35-42. [CrossRef]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.